Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer

APMIS

Volumn 122, Issue 2, 2014, Pages 140-146

  Li, Ying Na ^a   Zhang, Lin ^a   Li, Xiu Li ^a   Cui, Da Jiang ^a   Zheng, Hua Dong ^a   Yang, Shuan Ying ^b   Yang, Wei Lin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

GPNMB; Immunohistochemistry; Prognostic indicator; Small cell lung cancer

Indexed keywords

ETOPOSIDE; GLYCOPROTEIN; GLYCOPROTEIN NONMETASTATIC MELANOMA B; IRINOTECAN; PLATINUM; UNCLASSIFIED DRUG; GPNMB PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UPREGULATION; VERY ELDERLY; BLOOD; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS; SMALL CELL LUNG CARCINOMA; TISSUE ARRAY ANALYSIS;

EID: 84892850178     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12107     Document Type: Article

References (27)

1. Tang JH, Zhang XL, Zhang ZH, Wang R, Zhang HM, Zhang ZL, et al. Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review. Chin Med J 2011;124:563-8.
2. Hong S, Cho BC, Choi HJ, Jung M, Lee SH, Park KS, et al. Prognostic factors in small cell lung cancer: a new prognostic index in korean patients. Oncology 2010;79:293-300.
3. Chang MH, Lee K, Lee K-Y, Kim YS, Kim YK, Kang J-H. Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer. APMIS 2012;120:28-38.
4. Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer 2011;10:2-19.
5. Pietanza MC, Ladanyi M. Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet 2012;44:1074-5.
6. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-Reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 2012;53:111-7.
7. Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, Bonventre JV, et al. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J 2010;24:4767-81.
8. Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, et al. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res 2008;314:2334-51.
9. Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006;12:1970-82.
10. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
11. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003;278:15951-7.
12. Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007;60:423-35.
13. Rose AAN, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegell PM. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007;5:1001-14.
14. Onaga M, Ido A, Hasuike S, Uto H, Moriuchi A, Nagata K, et al. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 2003;39:779-85.
15. Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, et al. CR011, a fully human monoclonal anti body-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-82.
16. Rose AAN, Grosset AA, Dong ZF, Russo C, MacDonald PA, Bertos NR, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010;16:2147-56.
17. Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101:1455-62.
18. Skarda J, Fridman E, Plevova P, Hajduch M, Radova L, Ofek E, et al. Prognostic value of hMLH1 and hMSH2 immunohistochemical expression in non-small cell lung cancer. A tissue microarray study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150:255-9.
19. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009;15:1277-87.
20. Nitadori JI, Ishii G, Tsuta K, Yokose T, Murata Y, Kodama T, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol 2006;125:682-92.
21. Noh S, Shim H. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas. Lung Cancer 2012;76:51-5.
22. Rossi A, Maione P, Colantuoni G, Guerriero C, Ferrara C, Del Gaizo F, et al. Treatment of small cell lung cancer in the elderly. Oncologist 2005;10:399-411.
23. Otani Y, Kijima T, Kohmo S, Oishi S, Minami T, Nagatomo I, et al. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Lett 2012;586:3639-44.
24. Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien MER. Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 2010;102:629-38.
25. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60.
26. Hodkinson P, Mackinnon A, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007;83:733-41.
27. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202-15.